Alligator Bioscience has published preclinical data for ATOR-4066 i Cancer Immunology ResearchThe bispecific antibody, targeting CD40 and CEACAM5, was developed with the company's Neo-X-Primeplatform and RUBY-format. Data demonstrate tumor-localized activation of the immune system and synergistic effects with PD-1 inhibitors. ATOR-4066 represents the next step after mitazalimab in tumor-targeted CD40 agonists.
|
Published September 11, 2025
Alligator publishes preclinical data for ATOR-4066
Notes
Johnson & Johnson acquires Halda Therapeutics for $3 billion
Magle Group submits application for EmboCept S
Quia Pharma is delisted from Nasdaq
Stenocare acquires CannGros
Lundbeck enters the fight for Avadel
Klaria's partner CNX starts production of migraine film
Sofinnova Partners raises EUR 650 million in new fund
NEWSLETTER
Today's news roundup
News roundup Monday, November 17
Upcoming events
MedTech Summit 2026
A new, much-needed MedTech forum in one of Europe's leading life science clusters. As the first event of its kind...
Recommended
Pila Pharma stands out in next-generation obesity pipeline
Novo Nordisk challenges Pfizer in billion-dollar battle for Metsera
New major investment will strengthen Europe's life science sector
The pharmaceutical sector is riding a USD 61,6 billion R&D wave
SwedenBIO wants to give growth power to the industry
You deserve the best!
Unlock our premium content: Become a subscriber!
Create Account